NASDAQ:GALTGalectin Therapeutics Stock Price, Forecast & News

$2.95

-0.13 (-4.22 %)

(As of 05/28/2020 04:00 PM ET)

Add

Compare

Today's Range

$2.91

Now: $2.95▼

$3.10

50-Day Range

$1.72

MA: $2.38▼

$3.15

52-Week Range

$1.50

Now: $2.95▼

$4.50

Volume240,700 shs

Average Volume360,052 shs

Market Capitalization$168.24 million

P/E RatioN/A

Dividend YieldN/A

Beta2.46

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Galectin Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.50, Galectin Therapeutics has a potential upside of 120.3% from its current price of $2.95.
Amount of Analyst Coverage
Galectin Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Galectin Therapeutics has received 328 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Galectin Therapeutics has received 280 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Galectin Therapeutics has received 53.95% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Galectin Therapeutics and other stocks. Vote “Outperform” if you believe GALT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GALT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Galectin Therapeutics does not currently pay a dividend.
Dividend Growth
Galectin Therapeutics does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Galectin Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,140.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
40.70% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 18.40% of the stock of Galectin Therapeutics is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.36) to ($0.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Galectin Therapeutics is -10.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Galectin Therapeutics is -10.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Galectin Therapeutics has a P/B Ratio of 4.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.04 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:GALT

Previous Symbol

CUSIPN/A

CIK1133416

Webwww.galectintherapeutics.com

Phone678-620-3186

Debt

Debt-to-Equity RatioN/A

Current Ratio33.35

Quick Ratio33.35

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.71 per share

Price / Book4.15

Profitability

EPS (Most Recent Fiscal Year)($0.39)

Net Income$-13,290,000.00

Net MarginsN/A

Return on Equity-32.09%

Return on Assets-29.49%

Miscellaneous

Employees6

Outstanding Shares57,030,000

Market Cap$168.24 million

Next Earnings Date8/14/2020 (Estimated)

OptionableOptionable

Receive GALT News and Ratings via Email

Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.

Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions

How has Galectin Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Galectin Therapeutics' stock was trading at $1.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GALT shares have increased by 48.2% and is now trading at $2.95. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Galectin Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Galectin Therapeutics.

When is Galectin Therapeutics' next earnings date?

Galectin Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Galectin Therapeutics.

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) announced its quarterly earnings results on Monday, May, 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.02. View Galectin Therapeutics' earnings history.

What price target have analysts set for GALT?

2 analysts have issued 12-month price objectives for Galectin Therapeutics' stock. Their forecasts range from $4.00 to $9.00. On average, they expect Galectin Therapeutics' share price to reach $6.50 in the next twelve months. This suggests a possible upside of 120.3% from the stock's current price. View analysts' price targets for Galectin Therapeutics.

Has Galectin Therapeutics been receiving favorable news coverage?

News coverage about GALT stock has been trending very negative recently, according to InfoTrie. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Galectin Therapeutics earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutGalectin Therapeutics.

Are investors shorting Galectin Therapeutics?

Galectin Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 5,600,000 shares, an increase of 10.0% from the April 30th total of 5,090,000 shares. Based on an average daily volume of 283,900 shares, the days-to-cover ratio is presently 19.7 days. Currently, 13.7% of the company's stock are sold short. View Galectin Therapeutics' Current Options Chain.

Who are some of Galectin Therapeutics' key competitors?

Some companies that are related to Galectin Therapeutics include Morphic (MORF), Retrophin (RTRX), G1 Therapeutics (GTHX), Kala Pharmaceuticals (KALA), Assembly Biosciences (ASMB), Homology Medicines (FIXX), Ardelyx (ARDX), Sinovac Biotech (SVA), DiaMedica Therapeutics (DMCAF), Provention Bio (PRVB), Stemline Therapeutics (STML), Vanda Pharmaceuticals (VNDA), Crinetics Pharmaceuticals (CRNX), Radius Health (RDUS) and Syndax Pharmaceuticals (SNDX). View all competitors.

What other stocks do shareholders of Galectin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), Novavax (NVAX), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Synergy Pharmaceuticals (SGYP) and Verastem (VSTM).

Who are Galectin Therapeutics' key executives?

Galectin Therapeutics' management team includes the following people:

Dr. Harold H. Shlevin, Pres & CEO (Age 69)
Mr. Jack W. Callicutt, CFO & Sec. (Age 52)
Robert Tritt, Gen. Counsel
Dr. Eliezer Zomer, Exec. VP of Manufacturing & Product Devel. (Age 72)
Mr. J. Rex Horton, Exec. Director of Regulatory Affairs & Quality Assurance (Age 49)

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

Who are Galectin Therapeutics' major shareholders?

Galectin Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.48%), Advisor Group Holdings Inc. (1.52%), State Street Corp (1.16%), Geode Capital Management LLC (0.98%), Cambridge Investment Research Advisors Inc. (0.36%) and Nuveen Asset Management LLC (0.23%). Company insiders that own Galectin Therapeutics stock include Fund LP 10X, Gilbert F Amelio, Gilbert S Omenn, Harold H Shlevin, Jack W Callicutt, James C Czirr, Joel Lewis, Kary Eldred, Kevin D Freeman, Marc Rubin, Peter G Traber and Richard E Uihlein. View institutional ownership trends for Galectin Therapeutics.

Which institutional investors are selling Galectin Therapeutics stock?

GALT stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., UBS Group AG, Deutsche Bank AG, and State Street Corp. View insider buying and selling activity for Galectin Therapeutics.

Which institutional investors are buying Galectin Therapeutics stock?

GALT stock was bought by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., JPMorgan Chase & Co., Nuveen Asset Management LLC, Two Sigma Investments LP, Geode Capital Management LLC, Wells Fargo & Company MN, Cambridge Investment Research Advisors Inc., and SG Americas Securities LLC. Company insiders that have bought Galectin Therapeutics stock in the last two years include Jack W Callicutt, Joel Lewis, Kary Eldred, Kevin D Freeman, and Richard E Uihlein. View insider buying and selling activity for Galectin Therapeutics.

How do I buy shares of Galectin Therapeutics?

Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Galectin Therapeutics' stock price today?

One share of GALT stock can currently be purchased for approximately $2.95.

How big of a company is Galectin Therapeutics?

Galectin Therapeutics has a market capitalization of $168.24 million. The company earns $-13,290,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Galectin Therapeutics employs 6 workers across the globe.

What is Galectin Therapeutics' official website?

The official website for Galectin Therapeutics is www.galectintherapeutics.com.

How can I contact Galectin Therapeutics?

Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff